brain-penetrant LSD1 inh. for neuro. disorders

sociability improvement in vivo, completed Ph. I in HV

tranylcypromine class mechanism-based inh.

Sci. Adv., Mar. 12, 2021

Takeda Pharmaceuticals, Fujisawa, JP

The Takeda lysine-specific demethylase 1 (LSD1) inhibitor (TAK-418) is an oral CNS-penetrant clinical candidate for neurodevelopmental disorders such as autism spectrum disorder. We previously highlighted irreversible and reversible LSD1…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks